FDA approves Contrave for Chronic Weight Management- Takeda/Orexigen
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen Therapeutics, Inc. jointly announced that the FDA has approved Contrave (naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for Chronic Weight Management in adults with an initial body mass index (BMI) of 30 kg/m2or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins